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Abstract 
Objective - While initially seemingly paradoxical due to the lack of nucleus, platelets possess 
a number of transcription factors that regulate their function through DNA-independent 
mechanisms. These include the Farnesoid X Receptor (FXR), a member of the superfamily of 
ligand-activated transcription factors that has been identified as a bile acid receptor. In this 
study, we show that FXR is present in human platelets and FXR ligands, GW4064 and 6-
ECDCA, modulate platelet activation nongenomically. 
Approach and Results - FXR ligands inhibited the activation of platelets in response to 
stimulation of collagen or thrombin receptors, resulting in diminished intracellular calcium 
mobilization and secretion, fibrinogen binding and aggregation. Exposure to FXR ligands also 
reduced integrin IIb3 outside-in signaling and thereby reduced the ability of platelets to 
spread and to stimulate clot retraction.  FXR function in platelets was found to be associated 
with the modulation of cGMP levels in platelets and associated downstream inhibitory 
signaling.  Platelets from FXR-deficient mice were refractory to the actions of FXR agonists 
on platelet function and cyclic nucleotide signaling, firmly linking the non-genomic actions of 
these ligands to the FXR receptor. 
Conclusion – This study provides support for the ability of FXR ligands to modulate platelet 
activation.  The athero-protective effects of GW4064, with its novel antiplatelet effects, 
indicate FXR as a potential target for prevention of athero-thrombotic disease. 
 
 
Abbreviations 
FXR: farnesoid X receptor, cGMP: cyclic guanosine monophosphate, cAMP: cyclic 
adenosine monophosphate, CDCA: chenodeoxycholic acid, 6-ECDCA: 6-ethyl-
chenodeoxycholic acid, GPVI: glycoprotein VI, CRP-XL: cross-linked collagen-related 
peptide, Syk: spleen tyrosine kinase, LAT: linker for activation of T-cells, IBMX: 3-isobutyl-
1-methylxanthine, PDE: phosphodiesterase, PPAR: peroxisome proliferator-activated 
receptor, RXR: retinoid X receptor, LXR: liver X receptor, GR: glucocorticoid receptor, 
eNOS: endothelial nitric oxide synthase. 
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Introduction 
The farnesoid X receptor/bile acid receptor (FXR; NR1H4) is a member of the nuclear 
receptor superfamily of ligand-activated transcription factors that binds and acts as 
heterodimer with retinoid X receptors that have also been found to be expressed in human 
platelets, and is highly expressed in liver, kidney, adrenal glands, intestine and vascular 
tissues. 1-2 FXR regulates the expression of genes involved in cholesterol and glucose 
homeostasis, liver regeneration and gastrointestinal defense. 3-4 FXR has also been shown to 
have anti-inflammatory and athero-protective effects after ligand stimulation. 5 Endogenous 
ligands of FXR are bile acids with ligands including chenodeoxycholic acid (CDCA) and 
deoxycholic acid (DCA). 6 Synthetic FXR ligands have also been identified, such as GW4064 
and 6-ethyl-chenodeoxycholic acid (6-ECDCA). 7-8 FXR regulates the transcription of target 
genes through the induction of the atypical nuclear receptor small heterodimer partner (SHP), 
which mediates some of the inhibitory effects of FXR ligands on bile acid and lipid 
metabolism.9-10 
Platelets are anucleate blood cells with a central role in hemostasis but are also involved in 
inflammation, immunity, tumor progression and thrombosis. 11 Although lacking genomic 
DNA, platelets contain a diverse transcriptome, which allows signal-dependent protein 
translation and micro RNA processing.12-14 We and others have previously identified the 
presence of transcription factors in mammalian platelets, including peroxisome proliferator-
activated receptors (PPARs) 15-16, retinoid X receptor (RXR) 17, glucocorticoid receptor (GR) 
18, Liver X Receptor (LXR) 19, and the nuclear factor-B (NF-B). 20 Previous reports have 
demonstrated that FXR activation appears to protect against atherosclerotic plaque formation, 
5, 21 but these effects are more pronounced than expected, based on its lipid-lowering actions 
alone. 22 We therefore hypothesized that the athero-protective effects of FXR ligands may be 
mediated in part through potential modulation of platelet function. In this report, we 
demonstrate that FXR is present in platelets and that FXR ligands inhibit a range of platelet 
functions and thrombus formation, suggesting a potential new target for prevention of 
atherosclerosis and thrombosis based on acute DNA-independent actions of this receptor in 
platelets. 
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Materials and Methods 
Materials and Methods are available in the online-only Supplement. 
Results 
Presence of FXR in Platelets 
FXR protein expression was investigated in human and mouse platelets. Immunoblot analysis 
of cell lysates confirmed the presence of FXR in human and mouse platelets (Fig 1 A). The 
localization of FXR in human platelets was analyzed by immunofluorescence microscopy. In 
resting platelets FXR was found to be dispersed throughout the platelet cytoplasm in a 
punctate arrangement (Fig 1 Bi), while in response to U46619, a thromboxane A2 receptor 
(TP) agonist, the localization of FXR appeared to partially translocate towards the plasma 
membrane (Fig 1 Bii).   
FXR ligands inhibit platelet aggregation and secretion 
The effect of FXR-selective ligands GW4064 and 6-ECDCA on the aggregation of human 
washed platelets in response to activators of platelet function was explored. Platelet 
aggregation in response to CRP-XL (1 g mL-1), a glycoprotein VI (GPVI)-collagen receptor-
selective ligand, was found to be inhibited in a concentration-dependent manner by GW4064 
(Fig 2 A-B). Inhibition of 22%, 40%, and 80% was observed with GW4064 (1, 10 and 20 
M), which was more potent than 6-ECDCA in inhibiting platelet aggregation.  An increase 
in light transmission was observed on treatment with 10 and 20µM GW4064 that may be 
associated with platelet swelling. Consistent with inhibition of GPVI-mediated responses 
platelet aggregation in response to Collagen (0.5 µg mL-1) was also found to be inhibited in a 
concentration dependent-manner by GW4064.  In contrast, high concentrations of the natural 
FXR ligand CDCA, was required to produce an inhibitory effect on collagen-stimulated 
platelets (supplemental Fig 1). Differences in the potencies of GW4064, 6-ECDCA and 
CDCA in inhibiting platelet aggregation were in line with the differences in potency reported 
of these agonists in other cell systems. 8,  23 To determine whether the target for FXR ligands 
is shared with other agonists, thrombin, that activates platelets via G-protein-coupled 
receptors was tested, and used at a concentration that was optimized to ensure a similar level 
of aggregation to that stimulated by CRP-XL. Lower levels of inhibition were noted with 
thrombin-induced platelet aggregation (0.1 U mL-1) following treatment with GW4064 and 6-
ECDCA, although overall the inhibition profiles were similar. Inhibition of 5%, 35% and 
55% was observed with GW4064 (1, 10 and 20 M), (Fig 2 C, D).  Aggregation monitored 
over an extended period of 5 min duration confirmed this effect to be inhibition rather than 
delay in aggregation (data not shown).  
Platelet aggregation is dependent on conformational changes of integrin IIb3 through inside-
out signaling that results in an increase in its affinity for fibrinogen. 24 Thus, flow cytometry 
was used to measure fibrinogen binding to platelets, as a marker for activation of the integrin 
IIb3. CRP-XL-stimulated fibrinogen binding was reduced in the presence of GW4064 (Fig 2 
E), consistent with reduced aggregation and indicated the ability of the GW4064 to modulate 
inside-outside signaling to integrin IIb3 in platelets.  The effects of 6-ECDCA were 
insufficiently potent to elicit a statistically significant reduction in fibrinogen binding.  
Thrombus generation is supported and enhanced by the release of a number of substances 
from platelet alpha and dense granules, which are critical for the recruitment of additional 
platelets and for stabilization of the aggregate. 24-25 To analyze the effects of FXR agonist 
treatment on platelet granule secretion, - and dense-granule secretion were assayed in the 
absence and presence of GW4064 or vehicle (containing DMSO (0.1% (v/v)). -granule 
secretion was assessed by measuring the levels of P-selectin exposed on the surface of 
platelets after stimulation with CRP-XL (1 g mL-1) by flow cytometry in human whole 
blood. GW4064 caused a concentration dependent inhibition of P-selectin exposure (Fig 2 F) 
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reaching approximately 35% inhibition at a concentration of 20µM.  Consistent with less 
potent effects on aggregation, 6-ECDCA exhibited only modest effects on P-selectin 
exposure, reaching statistical significance at a concentration of 20µM.    
To investigate the role of FXR in dense granule secretion, ATP release was measured 
simultaneously with aggregation on washed platelet preparations using a luciferin-luciferase 
luminescence assay. GW4064 was found to reduce ATP secretion after CRP-XL stimulation 
(Fig 2 G).  Cytosolic mobilization of calcium plays a fundamental role in various aspects of 
platelet function, including reorganization of the actin cytoskeleton necessary for shape 
change, degranulation and integrin IIb3 affinity modulation. 26 We therefore examined the 
ability of FXR ligands to modulate intracellular mobilization of calcium. Fura-2AM-loaded 
PRP was pre-incubated with GW4064 (1-10 M) or control (containing DMSO (0.1% (v/v)) 
for 5 min and then stimulated with CRP-XL (1 g mL-1). Treatment with GW4064 was 
associated with a modest (in comparison with ATP secretion and other assays of function 
using washed platelets) inhibition of CRP-XL-stimulated peak calcium concentration (Fig 2 
H). 
The actions of GW4064 on platelets are mediated through FXR 
To confirm whether FXR is required for the inhibitory effect of FXR ligands on platelet 
function, the ability of GW4064 to inhibit platelet function in mice deficient in FXR was 
explored. We confirmed that the levels of integrin IIb3, integrin 21, GPVI and GPIb on 
the surface of FXR-/- platelets were similar to those from FXR+/+ mice (Supplemental data 
Fig 2). GW4064 (1-20 µM) treatment inhibited fibrinogen binding to FXR+/+ platelets upon 
stimulation with CRP-XL reaching approximately 50% inhibition at 20µM. This dramatic 
inhibition was not observed in FXR-/- platelets, although higher concentrations of GW4064 
did cause a modest reduction in fibrinogen binding (Fig 3).  These data confirm that the 
principal mode of action of FXR agonists on platelet function are mediated through binding to 
FXR 
FXR ligand, GW4064 affects integrin IIb3 mediated outside-in signalling  
Following binding to fibrinogen, integrin IIb3 clustering transduces signals (outside-in 
signalling) into platelets to allow spreading and in the latter phase of its formation, clot 
retraction. 27 The modulatory effects of GW4064 on outside-in integrin signalling through 
IIb3 were assessed by the measurement of clot retraction and platelet spreading under static 
conditions. Clot formation was initiated by adding thrombin to platelet-rich plasma in the 
absence or presence of GW4064 (1, 10 M), and the extent of clot retraction was monitored 
after 2 hours by measuring clot weight. Clot retraction was reduced in the presence of 
GW4064 (10 M) at 2 hours (indicated by increased clot weight) compared with vehicle-
treated samples (Fig 4 A-B). Consistent with this, GW4064-treated (10 M) platelets were 
unable to adhere and spread on fibrinogen to the same extent as control platelets at 45 min. 
Most GW4064-treated platelets failed to progress beyond filopodia formation with only a few 
cells progressing to lamellapodia formation and full spreading (Fig 4 C-D). These data 
suggest that outside-in signalling through IIb3, which controls the coordinated process of 
clot retraction, is also modulated by GW4064.  
GW4064 inhibits Thrombus Formation and hemostasis 
The integrin αIIbβ3 is critical for arterial thrombosis and hemostasis. Following platelet 
activation, the αIIbβ3 complex undergoes a conformational change that allows the adhesive 
protein fibrinogen to bind, forming a bridge between platelets that mediates platelet-platelet 
interactions and thrombus formation. 28-29 
Given the ability of FXR ligands to regulate platelet function, we sought to determine the 
potential implications of GW4064 on thrombus formation. Analysis of thrombus formation in 
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vitro was performed by fluorescence microscopy using DIOC6-labelled whole blood perfused 
under arterial flow conditions through Vena8 biochips coated with collagen, following pre-
incubation with GW4064 (1,10 M) or vehicle (containing DMSO (0.1% (v/v)) for 5 min. 
Blood was perfused for 10 min, after which thrombus development was assessed by 
measurement of fluorescence intensity. In comparison with control samples (Fig 5 A), 10 M 
GW4064 inhibited the thrombus fluorescence intensity by 65% (Fig 5 C-D). These data 
suggest that GW4064 is able to modulate thrombus formation under arterial flow conditions 
in whole blood. To determine whether the effects of GW4064 on thrombus formation in vitro 
were due to inhibition of initial entrapment of platelets on collagen, or due to the inhibition of 
platelet aggregation and therefore thrombus growth, perfusion of blood was also performed in 
the presence and absence of the IIb3 antagonist integrilin (4µM). In the presence of 
integrilin, GW4064 (10 μM) did not affect platelet adhesion to collagen suggesting that the 
FXR agonist does not modulate GPIb-dependent adhesion under flow (Supplemental Fig 3). 
These data indicate that the inhibition of thrombus formation by GW4064 is likely due to its 
ability reduce platelet activation following adhesion. 
To determine the potential impact of FXR on the acute regulation of platelet function in vivo, 
the effect of GW4064 on laser-induced thrombosis in mouse cremaster muscle arterioles was 
assessed. The effect of GW4064 infused intravenously prior to thrombus formation was 
explored and compared with thrombosis in vehicle-treated mice. Data analysis was performed 
for multiple thrombi formed in control and mice treated with GW4064. Following laser 
injury, thrombus formation was monitored for 180 seconds.  The initiation of thrombus 
formation was accelerated slightly, although the continued growth or stability of the thrombus 
were found to be reduced substantially in GW4064-treated mice compared with controls (Fig 
5 E-F). Inhibition of thrombus formation in the absence of endothelial cells (in vitro, Figure 5 
A-D) suggests that the inhibitory effects of GW4064 on thrombi formed in vivo are likely to 
be principally due to diminished platelet function, although indirect effects on platelet 
function mediated by other cells cannot be excluded. Taken together, these data establish a 
role for FXR ligands in the regulation of thrombosis.  
To assess the importance of FXR ligands for hemostasis, tail-bleeding assays were performed. 
The bleeding time after dissection of 1mm of tail tip was prolonged substantially in GW4064-
treated mice (between 195 and 797 seconds) compared with controls (between 96 and 299 
seconds) (Fig 5 G). These data are consistent with FXR agonists inhibiting platelet function 
and thereby suppressing hemostasis.  
GW4064 modulates platelet cyclic nucleotide signaling  
Due the inhibitory effects of FXR ligands on CRP-XL-induced aggregation, the 
phosphorylation levels of proteins involved early in the GPVI signaling pathway were 
assessed by immunoblot analysis. Platelet lysates were prepared after stimulation with CRP-
XL (1 g mL-1) in the presence of GW4064 (1-10 M) or vehicle (containing DMSO (0.1% 
(v/v)). The levels of total platelet protein tyrosine phosphorylation were unaffected after 
GW4064 treatment as were the tyrosine phosphorylation levels of the tyrosine kinase Syk and 
adapter protein LAT (key early components in the GPVI signalling pathways, Supplementary 
Fig 4).  Since early signaling stimulated by GPVI was unaffected and FXR ligands were 
found to inhibit the function platelet responses to GPVI agonists and thrombin, we explored 
whether FXR mediates its actions on platelets through the modulation of cyclic nucleotide 
signaling, mechanisms that provide powerful inhibition of platelet functional responses to a 
wide range of platelet activators. 
Nitric Oxide (NO) has both antithrombotic and vasodilatory effects. Under normal 
physiological conditions, the intact endothelium releases NO and prostacyclin to inhibit 
platelet adhesion and platelet aggregation by elevating the second messenger cyclic guanosine 
monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) respectively. 31-32  The 
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levels of cGMP and cAMP in GW4064-treated platelets were therefore measured following 
stimulation with CRP-XL. We first confirmed that we were able to measure cyclic nucleotide 
signaling in our experimental system.  Consistent with expectations, the levels of cGMP (Fig 
6A) were elevated on addition of the NO-donor PAPA nonoate (10 M). In agreement with a 
recent report, treatment with the NO donor also resulted in an increase in cAMP levels (Fig 
6B). 35  The addition of GW4064 increased cGMP but not cAMP levels over the range of 
concentrations used in CRP-stimulated platelets (Fig 6A-B). Cyclic nucleotide levels are up 
regulated by synthesis through adenylyl cyclase and guanylyl cyclase and down regulated by 
degradation through phosphodiesterases (PDEs). 33 To establish if GW4064 increased cGMP 
levels were dependent on the modulation of PDEs, PDE activity was measured using cGMP 
and cAMP as substrates. The phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine 
(IBMX), as expected, was able to inhibit PDE activity by 25% and 40% at concentrations of 
10 and 40 M, respectively. GW4064 (1-20 M) did not show any inhibitory effects on PDE 
activity with both cGMP or cAMP (Fig 6 C-D) degradation unaffected by treatment with 
GW4064. Taken together, these data suggest that inhibition of platelet function by GW4064 is 
regulated by increased synthesis of cGMP and not through increased hydrolysis of this cyclic 
nucleotide. 
The inhibitory effect of FXR on cyclic nucleotide signalling in platelets  
To analyze the potential requirement of FXR for the previously observed ability of GW4064 
to modulate platelet cGMP signalling (Fig 6A), the ability of GW4064 to elevate platelet 
cGMP levels in mice deficient in FXR was explored. The levels of cGMP were increased 
significantly on addition of the NO-donor PAPA nonoate (10 μM) to both FXR-/- and 
FXR+/+ platelets. The addition of GW4064 (10 μM) increased cGMP levels in CRP-
stimulated FXR+/+, although in FXR-/- platelets intracellular cGMP levels were unchanged 
(Fig 7 A).  
The vasodilator-stimulated phosphoprotein (VASP) is a critical protein involved in 
cytoskeletal remodelling and regulating adhesive events that are involved in platelet 
activation. 34 As an established marker of platelet inhibition and antiplatelet drug therapy, 35 
VASP is an effector that mediates cGMP-dependent inhibitory mechanisms in platelets. On 
elevation of cGMP, the cGMP-dependent protein kinase G (PKG) phosphorylates VASP at 
position S239. 
To further investigate whether GW4064 regulates cGMP-mediated inhibitory signalling in 
mice deficient in FXR, the phosphorylation of VASP at S239 was assessed by flow cytometry 
using phospho-specific antibodies. 35  On addition of the NO-donor PAPA nonoate (10 μM) 
VASP phosphorylation at S239 was increased in both FXR+/+ and FXR-/- mouse platelets 
(Fig 7 B).  Treatment with GW4064 (10 μM) was found to increase phosphorylation of VASP 
at S239 in FXR+/+ platelets, where FXR-/- platelets were unresponsive to GW4064 treatment 
(Fig 7 B).  These data indicate that the inhibitory effects of FXR ligands, mediated through 
the modulation of cGMP signalling in platelets may be attributed to their actions on FXR.  
 
Discussion 
Dyslipidemia is a major risk for cardiovascular disease and is associated with atherosclerosis 
and thrombotic complications. 36, 37 Inappropriate activation of platelets in the circulation is 
the major cause of atherothrombosis. 33 Current approaches for suppression of platelet 
function to prevent thrombosis with aspirin and ADP receptor antagonists are associated with 
serious bleeding side-effects. Thus, thrombotic disease remains a principal cause of mortality 
and morbidity worldwide, with increasing rates of incidence of these and underlying obesity-
related metabolic disorders. 38 Therefore, more efficacious and safer approaches are required. 
FXR is a key regulator of lipid and glucose metabolism, and FXR synthetic ligands have been 
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shown to have athero-protective effects, possibly through modulation of combined metabolic 
and vascular effects. 39. While platelets are anucleate cells, the presence of transcription 
factors in mammalian platelets have been reported, including PPARs, RXR, LXR, GR and the 
nuclear factor-B. 15-20  
PPARs are a family of ligand-activated nuclear receptors that, similarly to FXR, bind 
regulatory elements in responsive genes after the formation of a heterodimeric complex with 
RXR. 39 We have shown previously that PPAR interacts with Syk and LAT on the 
stimulation of platelets with collagen, and PPAR ligands cause loss of these associations. 30 
This is important, since these signaling proteins perform critical roles early in the signalling 
pathway that is stimulated by the platelet collagen receptor GPVI.  More recently, we 
suggested that the ability of LXR-PPAR to interact might be based on bidirectional 
association either with other nuclear receptors or components of the GPVI signaling pathway 
in the presence or absence of their ligands. 19 In the current study, we therefore evaluated the 
effects of FXR ligands on platelet function and thrombus formation and characterized 
potential mechanisms of action. 
Our data demonstrate that FXR ligands are able to modulate multiple aspects of platelet 
function stimulated by adhesion receptors, GPCR agonists and through integrin signaling. The 
FXR ligand, GW4064 did not cause marked inhibition of CRP-XL-induced tyrosine 
phosphorylation of Syk or LAT, suggesting that FXR does not serve to modulate the initiation 
of cell signaling mechanisms that are stimulated by GPVI and that more general downstream 
mechanisms with the potential to prevent activation through different platelet agonists must 
be involved.  
FXR has been proposed to be a novel and promising therapeutic target to the treatment of 
atherosclerosis and heart diseases. 42  The implications of FXR activation for vascular 
function is subject of debate. A previous study suggested that chronic stimulation of FXR 
with GW4064 impaired endothelium-dependent relaxation due to decreased sensitivity of 
smooth muscle cells to NO. 23 As FXR ligands are able to inhibit the function of platelets, and 
they possess the ability to modulate NO signaling in vascular cells 23,43, we sought to 
determine whether the acute actions of GW4064 may modulate cyclic nucleotide signaling in 
platelets.  Indeed, such signaling, in common with the observed effects of FXR agonists, is 
known to suppress platelet activation that is stimulated by a range of different platelets 
agonists, resulting in reduced intracellular calcium mobilisation, secretion, fibrinogen binding 
and aggregation.     
Our study revealed that FXR ligands are able to modulate platelet function by increasing 
cGMP levels, which is not mediated through the inhibition of PDEs in platelets. GW4064 was 
found to increase the phosphorylation of VASP at position S239 in FXR+/+ platelets, which 
is regulated by cGMP-mediated signalling. Consistent with this, the FXR-/- platelets were 
unresponsive to the actions of GW4064 on cGMP accumulation and VASP phosphorylation 
at S239. These data indicate that the inhibitory effects of the FXR ligand GW4064, which are 
associated with increased intracellular accumulation of cGMP, may be attributed to its ability 
to activate FXR in these cells.   In recent years, the presence of endothelial nitric oxide 
synthase in platelets has become a subject of debate with some studies showing its presence 
and function, 45, 46 and others its absence 47, 48.   We have no evidence for a direct role for FXR 
in stimulating NO generation, although whether through platelet eNOS, or NO generated by 
platelets through other means, this remains a potential axis through which the acute effects of 
FXR in platelets may be mediated.  
Further work will be required to explore in detail the mechanism through which FXR 
modulates cyclic nucleotide signaling in platelets. It is important to note that FXR ligands 
modulate platelet function in an acute and clearly non-genomic manner. Whether the effects 
of FXR ligands on platelets are related to their shared abilities to regulate the effects of 
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vascular NO (which have also been attributed to genomic actions of FXR) or other target 
molecules remains to be established. 
Due to its roles in lipid and glucose metabolism, FXR has become a target for drug discovery. 
Bile acids are the major metabolites of cholesterol that exert genomic and non-genomic 
effects by activating the FXR. 49 They are produced in the liver and are secreted into the small 
intestine where they facilitate the absorption of dietary and biliary lipids including 
cholesterol. Targeting bile acid metabolism and the enterohepatic circulation has, therefore, 
been considered an attractive mechanism for treating dyslipidemia. 36 Normal levels of bile 
acids in the systemic circulation were reported to be ≥ 10 µM in posprandial conditions. 50, 51 
Bile acids have previously been associated with platelet dysfunction 52 although to date, little 
is known about the interactions between bile acids and platelet signalling. A previous study 
reported that Taurocholic acid inhibits platelet activation and promotes fibrinolysis, however, 
whether the effects of Taurocholic acid on platelet function are related to their shared abilities 
to regulate bile acid metabolism or other target molecules remains to be established. 53   
Whether FXR agonists may be considered in the development of anti-thrombotic agents will 
require thorough evaluation of their potential to limit thrombosis, while balancing the need 
for effective hemostasis.  Notably, this study demonstrates that 10 µM GW4064 is able to 
inhibit moderately platelet function in vitro and in vivo, but it is also associated with enhanced 
bleeding in mice. Emerging evidence suggests that GW4064 is able to decrease plasma 
triglycerides and insulin resistance in genetic mouse models of obesity. 36 Furthermore, 
several pre-clinical animal studies have demonstrated that synthetic FXR ligands protect 
against development of aortic plaque formation in models of atherogenesis. 54 The analysis of 
FXR deficient mice has demonstrated that despite a pro-atherosclerotic profile these mice did 
not spontaneously develop plaques even with a high fat diet. Together these lines of evidence, 
combined with the outcomes of the present study suggest a complex mechanistic role for FXR 
in the pathogenesis of atherosclerosis that might arise from the combined metabolic and 
vascular effects. 36, 54, 55  
Our study provides evidence that FXR is present in platelets and that its ligands inhibit 
platelet function and thrombus formation, suggesting a potential new axis for prevention of 
atherosclerosis and thrombosis based on acute non-genomic actions of this receptor in 
platelets. 
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Highlights 
 The farnesoid X receptor (FXR) acutely regulates platelet function in a non-genomic 
manner 
 FXR ligands cause inhibition of platelet activation, secretion, aggregation, thrombus 
formation, hemostasis and thrombosis 
 FXR controls platelet function through the modulation of cyclic guanosine 
monophosphate (cGMP) signaling 
 
FIGURE LEGENDS 
Figure 1 – FXR is expressed in human and mouse platelets. (A) Whole human and mouse 
platelet lysates, samples from 3 separate donors or mice, were immunoblotted (IB) to detect 
FXR.  The localization of FXR in human platelets was analysed by immunofluorescence 
confocal microscopy. (B) Unstimulated (i) and stimulated (using U46619 (20µM) in the 
presence of Integrilin (4µM)) platelets (ii) in PRP were fixed in 4% (v/v) paraformaldehyde-
PBS. Platelets were permeablised (in the presence of 0.2% triton X-100, donkey serum and 
1% PBS-BSA) and stained for FXR (in red) and GPIb (in green). Visualisation of cells was 
performed using a Nikon A1-R confocal microscope and 100x oil immersion lens. In resting 
and activated platelets, FXR was found to be dispersed throughout the platelet volume in a 
punctate arrangement.  Line plot analysis was performed across resting and stimulated 
platelets that also indicated partial re-localisation of FXR towards the plasma membrane 
following activation. The data for line plots are representative of >7 cells (representative data 
shown). 
Figure 2 - FXR ligands inhibit platelet activation. Washed human platelets were treated for 5 
min with increasing concentrations of FXR ligands, GW4064, 6-ECDCA or vehicle 
containing (DMSO (0.1% (v/v)), prior to stimulation for 180s with collagen-related peptide 
CRP-XL (1 g mL-1) or Thrombin (0.1 U/mL) and aggregation measured at 37C under 
constant stirring conditions (A-D). The effect of GW4064 and 6-ECDCA on fibrinogen 
binding and P-selectin exposure prior to stimulation with CRP-XL (1 g mL-1) were 
measured in human whole blood by Flow cytometry (E-F). Changes in ATP concentration 
released by washed platelets stimulatied for 180s with CRP-XL (1 g mL-1) were used as a 
measure of dense-granule secretion and monitored simultaneously with aggregation in an 
optical lumi-aggregometer using a luciferase detection system (G). Calcium mobilization was 
assessed in Fura-2AM-loaded PRP pre-incubated with increasing concentration of GW4064 
in the presence of EGTA to prevent influx of extracellular calcium and then stimulated with 
CRP-XL (1 g mL-1) (H). Numerical data represent the percentage compared with control, 
mean ± SD (n=4).*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.005, ****P≤0.001, (ANOVA with 
Bonferroni post test). 
Figure 3 - The actions of GW4064 on platelets are mediated through FXR. Blood from 
FXR+/+ and FXR-/- mice was treated with GW4064 or vehicle (containing DMSO 0.1% (v/v)) 
for 20 min prior stimulation with CRP-XL (1 g mL-1) and fibrinogen binding measured by 
flow cytometry.  Data (median fluorescence intensity, expressed as a percentage of fibrinogen 
binding in the absence of GW4064) represent FXR-/- mice platelets compared with FXR+/+ 
mice platelets (control), mean ± SD (n=4), *P ≤ 0.05, **P ≤0.01 (t-test). 
Figure 4 – GW4064 inhibits integrin IIb3-mediated outside-in signalling. Effect of GW4064 
on clot retraction was analyzed in vitro (A-B). Representative images of clot retraction at 2h 
in the presence and absence of GW4064 (1, 10 μM), (A). GW4064 affects spreading in a 
concentration-dependent manner. Washed human platelets were allowed to spread for 45 min 
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in the presence and absence of GW4064 (1 – 20 μM) on 100 g mL-1 fibrinogen-coated cover 
glasses and stained with Alexa fluor 488 labelled phalloidin prior to analysis by confocal 
microscopy (C). The images were analysed and the number of platelets found at different 
stages of platelet spreading were calculated (D). Numerical data represent the percentage 
compared with control, mean ± S.E.M. (n=4). *P ≤ 0.05, ANOVA with Bonferroni post test. 
Figure 5 – GW4064 inhibits thrombus formation and hemostasis. Human whole blood 
labelled with the (DiOC6)-lipophilic dye 3,3-dihexyloxacarbocyanine iodide was treated with 
vehicle (containing DMSO (0.1% (v/v)) (A) or GW4064 (1, 10 μM) (B-C) for 5 min and 
perfused through collagen-coated (400 g mL-1) Vena8Biochips at a shear rate of 20 dyn/cm2. 
Thrombi were recorded at 10 min period through a series of images in the Z-plane through 
their full depth using a Nikon eclipse (TE2000-U) microscope, and thrombus fluorescence 
intensity was calculated using the Slidebook, version 5. The fluorescence intensity of thrombi 
obtained in the absence of GW4064 was taken as 100% (D). Cumulative data represent 
mean±SD (n=6), P * ≤ 0.05, **P ≤0.01 (t-test).  In vivo thrombosis was assayed using a laser 
injury model by intravital microscopy. GW4064-estimated concentration (10 μM) or vehicle 
(containing DMSO (0.1% (v/v)) was administered intravenously to mice, and platelets were 
fluorescently labeled by injection of Alexa 488-conjugated anti-GPIb antibody. After laser-
induced injury of the cremaster muscle arterioles, accumulation of platelets was assessed. 
Representative images of thrombi obtained from mice treated with or without GW4064 at 
different time intervals are shown (E). Mean fluorescence intensity was measured from 
control and GW4064-treated mice (n≥16 thrombi from 4 GW4064-treated and 4 control mice) 
(F). The effect of GW4064 on hemostasis of mice was analyzed by measuring the bleeding 
time after tail tip excision. The bleeding time obtained with vehicle-treated group was 
compared with GW4064-treated mice (G). Data represent mean±SD (n=10 for each vehicle 
and mice-treated group), Statistical analysis was performed using the nonparametric Mann-
Whitney test (p=0.004).  
Figure 6 – GW4064 modulates platelet cyclic nucleotide signaling. The levels of cGMP (A) 
and cAMP (B) were measured in platelets on stimulation with CRP-XL (1 μg/mL) in the 
presence of GW4064 (1-10 μM) that was found to selectively increase cGMP levels.  The 
effects of GW4064 (1-10 μM) on phosphodiesterase activity were measured on the hydrolysis 
of cGMP (C) and cAMP (D) to establish whether this corresponded to greater cyclic 
nucleotide production or hydrolysis. While the phosphodiesterase inhibitor IBMX inhibited 
cGMP and cAMP hydrolysis, GW4064 was without effect. The level of phosphodiesterase 
activity obtained in the absence of GW4064 was taken as 100%. Data represent mean±SD 
(n=3), P *** ≤ 0.005, ***P ≤0.001,  (ANOVA with Bonferroni post test).  
Figure 7 – Platelet FXR mediates cGMP signaling. Platelets derived from FXR+/+ and FXR-/- 
mice were treated with GW4064 or vehicle containing (DMSO (0.1% (v/v)) for 20 min prior 
stimulation with CRP-XL (1 g mL-1).  (A) cGMP levels were measured using the Enzyme 
immunoassay Biotrak (EIA) system and (B) VASP phosphorylation levels (S239) assessed by 
flow cytometry. R represents untreated resting platelet samples. Data represent FXR-/- mice 
platelets compared with FXR+/+ mice platelets (control), mean ± SD (n=4), *P ≤ 0.05, **P 
≤0.01, ***P ≤0.005, ****P ≤0.001 (ANOVA with Bonferroni post test). 
 
